Uncategorized
Uncategorized
Advertisement
Ruben Mesa, MDUncategorized | June 7, 2024
In the last segment of the roundtable series, the panel discusses the future of myelofibrosis treatment.
Ruben Mesa, MDUncategorized | July 2, 2024
The panel discusses the four JAK inhibitors approved by the FDA: ruxolitinib, fedratinib, pacritinib, and momelotinib.
Ruben Mesa, MDThe HemOnc Pulse Live | June 7, 2024
In the sixth segment of the roundtable series, the panel discusses momelotinib and pacritinib treatment in myelofibrosis.
Ruben Mesa, MDThe HemOnc Pulse Live | June 7, 2024
The panel discusses fedratinib for myelofibrosis and whether it's used in the frontline or second line setting.
Ruben Mesa, MDThe HemOnc Pulse Live | June 7, 2024
In the fourth segment of the roundtable series, the panel discusses frontline ruxolitinib treatment for myelofibrosis.
Ruben Mesa, MDThe HemOnc Pulse Live | June 7, 2024
This roundtable session addresses which patients go directly to transplant, when to observe patients, and more.
Advertisement
Ruben Mesa, MDVideo Insights | June 7, 2024
In the first segment of the roundtable series, the panel discusses how myelofibrosis is diagnosed and assessed.
Ruben Mesa, MDVideo Insights | June 7, 2024
Dr. Naveen Pemmaraju discusses the history of prognostic scoring systems and how they factor into frontline therapy planning.
Sanam Loghavi, MDThe HemOnc Pulse Live | May 13, 2024
“I’m grateful to shed a spotlight on hematopathology and what we contribute to these patients," Dr. Loghavi said.
Amer Zeidan, MBBS, MHSThe HemOnc Pulse Live | May 13, 2024
Dr. Zeidan will be participating in the myelodysplastic syndromes panel on the second day of the event
Advertisement
Advertisement
Editorial Board